Atigotatug
Based on 1 Customer Validation
Atigotatug (BMS-986012) is a fully human IgG1 antibody binds specifically to FucGM1 with an EC50 of 0.15 nmol/L for FucGM1. Atigotatug is a FcγRIIIa ligand with a Kd of 21 nmol/L. Atigotatug demonstrates antitumor efficacy in multiple mouse small cell lung cancer models.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: ≥99.0%
- CAS 番号: 2733581-82-1
- 分子量:146.06 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human IgG1 kappa
Human
Fucosyl ganglioside GM1
Atigotatug (serial dilutions) specifically binds purified FucGM1 antigen with an EC50 of 0.15 nmol/L[1].
Atigotatug (serial dilutions) mediates potent ADCC against DMS79 SCLC cells with an EC50 of 0.06 nmol/L[1].
Atigotatug (serial dilutions; 4 hours at 37 °C) mediates CDC against DMS79 SCLC cells with an EC50 of 59 nmol/L following 4 hours of incubation at 37 °C with human complement[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID[1]
-
Dosage:10 mg/kg
-
Administration:three times per week; 3 weeks
-
Result:Induced complete tumor regression in PDX model LU5202 (H-score = 290, high FucGM1 expression).
Achieved 75% TGI 22 days after initial dosing in PDX model LU5170 (H-score = 265, intermediate FucGM1 expression).
Showed no TGI in PDX model LU5249 (H-score = 65, low FucGM1 expression).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 2733581-82-1
-
性状 Liquid
-
分子量 146.06 kDa
-
Color Colorless to light yellow
-
SMILES
[Atigotatug]
-
別名
BMS-986012
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Ponath P, et al. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res. 2018 Oct 15;24(20):5178-5189. [Content Brief]
[2]. Paz-Ares LG, et al. TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. Published online January 26, 2026. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Atigotatug 関連分類
HY-P990902 関連分類
Powered by Bioz
- Atigotatug
- 2733581-82-1
- BMS-986012
- BMS986012
- BMS 986012
- Transmembrane Glycoprotein
- cisplatin
- mouse small cell lung cancer models
- antibody-dependent cellular cytotoxicity
- fucosyl-GM1
- complement-dependent cytotoxicity
- FcγRIIIa
- anti-PD-1
- etoposide
- small cell lung cancer cells
- antibody-dependent cellular phagocytosis
- Inhibitor
- inhibitor
- inhibit